Wedbush Securities’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$203K Buy
+1,108
New +$204K 0.01% 1129
2025
Q4
Sell
-2,017
Closed -$283K 1209
2025
Q3
$283K Buy
2,017
+46
+2% +$6.22K 0.01% 888
2025
Q2
$248K Buy
1,971
+436
+28% +$54.3K 0.01% 937
2025
Q1
$210K Buy
+1,535
New +$219K 0.01% 988
2024
Q4
Sell
-1,103
Closed -$214K 1145
2024
Q3
$214K Sell
1,103
-338
-23% -$70.7K 0.01% 963
2024
Q2
$334K Sell
1,441
-289
-17% -$62.8K 0.01% 808
2024
Q1
$373K Buy
1,730
+185
+12% +$43.3K 0.01% 765
2023
Q4
$400K Sell
1,545
-47
-3% -$11.5K 0.02% 643
2023
Q3
$409K Buy
1,592
+16
+1% +$4.28K 0.02% 593
2023
Q2
$449K Sell
1,576
-400
-20% -$119K 0.02% 582
2023
Q1
$549K Buy
1,976
+67
+4% +$18.5K 0.03% 488
2022
Q4
$529K Sell
1,909
-53
-3% -$15K 0.03% 494
2022
Q3
$524K Sell
1,962
-74
-4% -$15.7K 0.03% 501
2022
Q2
$415K Buy
2,036
+204
+11% +$41.7K 0.02% 600
2022
Q1
$386K Sell
1,832
-695
-28% -$151K 0.02% 684
2021
Q4
$606K Buy
2,527
+113
+5% +$29.1K 0.03% 542
2021
Q3
$683K Buy
2,414
+76
+3% +$24.9K 0.03% 475
2021
Q2
$810K Sell
2,338
-320
-12% -$96.9K 0.04% 423
2021
Q1
$744K Buy
2,658
+922
+53% +$249K 0.04% 425
2020
Q4
$425K Sell
1,736
-335
-16% -$86.4K 0.04% 521
2020
Q3
$588K Sell
2,071
-30
-1% -$8.37K 0.06% 372
2020
Q2
$562K Sell
2,101
-261
-11% -$78.5K 0.05% 379
2020
Q1
$747K Buy
2,362
+22
+0.9% +$6.68K 0.09% 244
2019
Q4
$694K Sell
2,340
-179
-7% -$49.7K 0.06% 356
2019
Q3
$586K Buy
2,519
+276
+12% +$64.3K 0.06% 386
2019
Q2
$525K Sell
2,243
-793
-26% -$183K 0.05% 411
2019
Q1
$718K Sell
3,036
-894
-23% -$282K 0.08% 302
2018
Q4
$1.18M Sell
3,930
-89
-2% -$28.4K 0.15% 164
2018
Q3
$1.42M Buy
4,019
+218
+6% +$75.1K 0.16% 139
2018
Q2
$1.1M Buy
3,801
+363
+11% +$102K 0.14% 171
2018
Q1
$941K Sell
3,438
-202
-6% -$62.7K 0.12% 202
2017
Q4
$1.16M Buy
3,640
+144
+4% +$46.2K 0.14% 162
2017
Q3
$1.09M Buy
3,496
+1
+0% +$296 0.14% 156
2017
Q2
$948K Sell
3,495
-97
-3% -$25.6K 0.12% 202
2017
Q1
$982K Sell
3,592
-172
-5% -$48.6K 0.13% 186
2016
Q4
$1.07M Sell
3,764
-449
-11% -$133K 0.16% 147
2016
Q3
$1.32M Sell
4,213
-27
-0.6% -$8K 0.2% 108
2016
Q2
$1.02M Sell
4,240
-520
-11% -$137K 0.17% 129
2016
Q1
$1.24M Buy
4,760
+1,461
+44% +$386K 0.22% 102
2015
Q4
$1.01M Sell
3,299
-781
-19% -$224K 0.18% 117
2015
Q3
$1.19M Buy
4,080
+713
+21% +$235K 0.24% 93
2015
Q2
$1.36M Buy
3,367
+538
+19% +$216K 0.25% 85
2015
Q1
$1.2M Buy
2,829
+1,273
+82% +$502K 0.2% 104
2014
Q4
$528K Buy
1,556
+135
+10% +$43.7K 0.08% 253
2014
Q3
$470K Buy
1,421
+400
+39% +$132K 0.07% 281
2014
Q2
$322K Buy
1,021
+111
+12% +$33.4K 0.05% 363
2014
Q1
$278K Buy
910
+71
+8% +$22.5K 0.05% 392
2013
Q4
$235K Hold
839
0.06% 406
2013
Q3
$202K Buy
+839
New +$188K 0.05% 434

Other funds holding BIIB

Wedbush Securities's BIIB Position: Q1 2026 in Review

Wedbush Securities opened a new position in Biogen (BIIB) in Q1 2026: 1,108 shares worth $203K. The stake represents 0.01% of the portfolio and ranks #1129 among its holdings. This is a return to the name: Wedbush Securities previously reported a position in BIIB as recently as Q3 2025.

Wedbush Securities first reported a position in BIIB in Q3 2013 and has held it in 49 quarters since. The position peaked at $1.42M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Wedbush Securities held 1,108 shares of Biogen worth $203K as of Q1 2026.
  • Biogen was a new Wedbush Securities position in Q1 2026.
  • Biogen made up 0.01% of Wedbush Securities's portfolio in Q1 2026, its #1129 holding.
  • Wedbush Securities first reported a position in Biogen in Q3 2013 and has held it in 49 quarters since.
  • Wedbush Securities's Biogen position peaked at $1.42M in Q3 2018.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.